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Abstract
Background: The Orthopoxvirus genus contains numerous virus species that are capable of causing disease in
humans, including variola virus (the etiological agent of smallpox), monkeypox virus, cowpox virus, and vaccinia
virus (the prototypical member of the genus). Monkeypox is a zoonotic disease that is endemic in the Democratic
Republic of the Congo and is characterized by systemic lesion development and prominent lymphadenopathy.
Like variola virus, monkeypox virus is a high priority pathogen for therapeutic development due to its potential to
cause serious disease with significant health impacts after zoonotic, accidental, or deliberate introduction into a
naïve population.
Results: The purpose of this study was to investigate the prophylactic and therapeutic potential of interferon-b
(IFN-b) for use against monkeypox virus. We found that treatment with human IFN-b results in a significant
decrease in monkeypox virus production and spread in vitro. IFN-b substantially inhibited monkeypox virus when
introduced 6-8 h post infection, revealing its potential for use as a therapeutic. IFN-b induced the expression of the
antiviral protein MxA in infected cells, and constitutive expression of MxA was shown to inhibit monkeypox virus
infection.
Conclusions: Our results demonstrate the successful inhibition of monkeypox virus using human IFN-b and
suggest that IFN-b could potentially serve as a novel safe therapeutic for human monkeypox disease.
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Background
The Orthopoxvirus genus of the family Poxviridae con-
tains a number of pathogens known to infect humans,
including variola virus (VARV, the causative agent of
smallpox), cowpox virus, camelpox virus, vaccinia virus,
and monkeypox virus (MPXV). Human infection with
members of this genus results in varying degrees of mor-
bidity and mortality. Virions are enveloped and brick-
shaped, with a dumbbell shaped core containing the
genetic material [1]. Orthopoxviruses contain a single, lin-
ear piece of double-stranded DNA with highly conserved
central regions and more variable terminal ends [1]. The
proteins expressed from the terminal ends are predomi-
nantly involved in immunomodulation and/or host range
determination [2-4].
VARV, the etiological agent of smallpox, causes an
acute, systemic lesional disease with a mortality rate of
approximately 30% [5,6]. Eradicated in 1977, smallpox
remains a constant threat due to its potential use as a bio-
logical weapon for mass dissemination to a largely unpro-
tected worldwide population. Unfortunately, VARV is not
the only member of the Orthopoxvirus genus that causes
severe disease in humans and has the potential for devel-
opment as a biological weapon. The global eradication of
smallpox and the subsequent cessation of smallpox vacci-
nation in 1980 allowed for the emergence of another lethal
zoonotic disease, monkeypox.
Similar to smallpox, monkeypox is a systemic lesional
disease with a prodrome period of flu-like symptoms
(fever, malaise, chills, headache) followed by the develop-
ment of a progressive maculopapular rash which expands
in a centrifugal pattern and progresses from papules to
vesicles to pustules and finally to crusts [7-11]. MPXV is
a zoonotic virus endemic in the Democratic Republic of
the Congo (DRC) where it regularly emerges from
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[12-14], to cause serious disease outbreaks in humans.
The best estimate of mortality rate is approximately 10%;
however, this is likely an underrepresentation due to
sporadic reporting since 1986 and a lack of information
concerning the complete geographic range of human
monkeypox disease [9,15-18].
There are 2 distinct clades of MPXV, West African and
Central African. MPXV strains belonging to the West
African clade are far less virulent than Central African
strains in both humans and non-human primates, with
diminished morbidity and human-to-human transmissibil-
ity [19,20]. The MPXV outbreak that occurred in the Mid-
western United States in 2003 was caused by a West
African strain of MPXV and thus resulted in less severe
disease than what is typically seen in outbreaks in Central
Africa [21]. This outbreak did, however, demonstrate the
ability of MPXV to reach beyond the African continent
and cause disease in MPXV-naïve populations. Although
outbreaks of Central African monkeypox have not been
seen outside of Africa, predictions based on an ongoing
active disease surveillance study in the DRC suggest that
spread to a MPXV-naïve population could have significant
public health impacts. This study was conducted in nine
health zones in the DRC and revealed a dramatic increase
in monkeypox cases, with 760 laboratory confirmed cases
identified from 2005 to 2007 [18]. Although previous vac-
cination against smallpox was found to still confer signifi-
cant protection, only approximately 25% of the population
in the sampled health zones had evidence of past vaccina-
tion [18]. Data suggesting that the incidence of human-to-
human transmission of MPXV is on the rise in this region
is also concerning [18,22] and could suggest that fading
herd immunity coincident with a rise in the number of
unvaccinated persons is allowing for more efficient spread.
Additionally, it is possible that genetic variants are emer-
g i n gt h a ta r em o r eh i g h l ya d a p t e dt oh u m a n s .T a k e n
together with a long incubation period, which allows for a
significant period of time during which a person is poten-
tially contagious but asymptomatic, and its potential use
as a biological weapon, it is evident that the development
of therapeutic methods to treat active MPXV infections is
critical.
In this paper, we investigate the potential use of inter-
feron (IFN)-b as an anti-MPXV therapeutic. IFN-b is
already US Food and Drug Administration (FDA)
approved for the treatment of multiple sclerosis in four
forms: Betaseron, Rebif, Avonex, and Extavia. All of these
products have well-defined safety records for human use
(FDA).
IFN-b is a type I IFN that plays a key role in the
innate immune response by promoting the production
of IFN-stimulated genes that inhibit protein synthesis,
induce apoptosis, and activate macrophages and natural
killer cells [23-25]. Additionally, type I IFNs enhances
t h ea d a p t i v ei m m u n er e s p o n s eb yu p r e g u l a t i n gm a j o r
histocompatibility complex-I/II expression on the sur-
face of antigen-presenting cells [23-25].
IFNs have been generally overlooked as anti-Orthopox-
virus agents due to the large number of immunomodula-
tory proteins expressed by viruses belonging to this genus.
To date, 13 Orthopoxvirus proteins have been shown to
have anti-IFN activity: A46, A52, K7, N1, B14, K1, M2,
COP-B19, B8, H1, E3, K3, and C7 [26]. Recently, a 14th
protein was identified, VARV-G1R, which binds to NF-B
and inhibits NF-B regulated gene expression [27]. Some
of these proteins have also been shown to play key roles in
host range determination and virulence during vaccinia
virus infection. Unfortunately, most of these proteins have
not been fully characterized, and the activity of orthologs
expressed by MPXV and VARV has not been extensively
investigated at this time. One of the best characterized of
these proteins is E3. E3 has been studied in vaccinia virus
and is known to block the activation of PKR [28-30].
Although VARV contains a full length and fully functional
E3L, MPXV lacks the N-terminal domain responsible for
binding Z-DNA and PKR [11,30,31]. Removal of this
domain results in a decreased virulence in murine models
of vaccinia infection [32]. K3 is a homolog of eIF-2a that
sequesters PKR thereby preventing phosphorylation of
native eIF-2a by PKR [33-35]. It is a host range gene that
is expressed by both VARV and vaccinia virus but not by
MPXV [11,36]. C7 and K1 have also been shown to affect
the cell tropism of vaccinia virus [37-40]. Although their
exact functions are less well understood, it is believed that
they employ a novel mechanism to antagonize IFN
[37,41]. While the role of VARV-G1 in host range restric-
tion has not been explicitly demonstrated, G1 orthologs
are present in some of the most highly pathogenic Ortho-
poxviruses, including VARV and MPXV, but not in vacci-
nia virus, suggesting that this protein may be a key
virulence factor [27].
The detailed comparative study of COP-B19 orthologs
from MPXV and VARV represents the first cross-species
functional analysis of any of the anti-IFN immunomodula-
tors [42]. In this study, COP-B19 (aka B18 or IFN a/bR)
from vaccinia virus was found to react very strongly with
human and murine IFN-a and IFN-b. In contrast, the
VARV ortholog, B17, bound to murine IFN-b very poorly
but bound to human IFN-b better than vaccinia B18.
Although this study didn’t give as detailed of a description
of the binding properties of MPXV B16, it did suggest that
immunomodulatory proteins such as COP-B19 may play
significant roles in host range restriction. Additionally, it
showed that the analysis of Orthopoxvirus immunomodu-
latory proteins cannot be limited to vaccinia virus but
must be carried out for all Orthopoxviruses as orthologs
may function differently and/or be affected to varying
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functional variability of the immunomodulatory proteins
necessitate that prophylactic or therapeutic agents that are
intended to overcome the action of these proteins be
tested for efficacy with all Orthopoxviruses as the suscept-
ibility of these viruses may vary significantly.
Although IFN-b has been shown to substantially dimin-
ish vaccinia virus pathogenesis in vivo [43,44], the suscept-
ibility of MPXV to IFN-b is uncertain. In this study, we
found that MPXV production and release were signifi-
cantly reduced in the presence of IFN-b. Additionally,
IFN-b was able to inhibit MPXV when introduced 6-8 h
after infection, revealing its potential for use as a therapeu-
tic against established infections. IFN-b treatment was able
to induce the expression of the antiviral protein MxA dur-
ing MPXV infection, and constitutive expression of MxA
was able to inhibit virus production. Collectively, the data
show that IFN-b is a strong novel candidate for further
investigation as a prophylactic and therapeutic against
MPXV.
Results
MPXV was inhibited by IFN-b
Although IFN-b has been used alone and in combination
with other cytokines in studies involving vaccinia virus,
the response of MPXV to IFN-b treatment had not been
previously investigated. HeLa cells that were pre-treated
for 24 hours (h) before infection with increasing concen-
trations of IFN-b (0-5000 units [U]/ml) were infected with
MPXV-Zaire at a high multiplicity of infection (MOI).
The cells were harvested 24 h post infection (p.i.) and
virus present titered by plaque assay. Titration results indi-
cated that MPXV was susceptible to inhibition by IFN-b
with concentrations as low as 600 U/ml, and an optimal
approximately 91% reduction was seen with 2000 U/ml of
IFN-b (Figure 1a). Examination of IFN-b treated HeLa
cells using the CellTiter-Glo Luminescent Cell Viability
Assay (Promega, Madison, WI) confirmed that there was
no observable toxicity from IFN treatments (Figure 1a).
Based on the dose response curves and lack of observable
cellular toxicity, a 2000 U/ml 24 h pre-treatment was
selected for further experimentation.
To specifically investigate infectious virus production and
release in the presence of IFN-b, a high MOI growth curve
using MPXV-Zaire was performed. Although virus replica-
tion still occurred in cells treated with IFN-b,w eo b s e r v e d
an approximately 1 log reduction in cell-associated and
released virus 24-48 h p.i. in the presence of IFN-b com-
pared to untreated controls (Figure 1b).
The recombinant virus MPXV-GFP-tdTR, which
expresses green fluorescent protein (GFP) from an early
MPXV promoter and Tomato Red (TR) from a late MPXV
promoter, allows visualization of early and late gene
expression. Fluorescence microscopy of recombinant
plaques demonstrated uniform distribution and complete
colocalization of GFP and TR signal (Figure 2a). Cells
infected in the presence of cytosine-b-D-arabinofuranoside
(Ara-C), which allows early gene expression but inhibits
DNA replication and subsequently late gene expression,
showed a complete knockdown of only TR expression
(Figure 2b), verifying the expression profile of GFP and TR.
At i m ec o u r s ee x p e r i m e n tu sing flow cytometry also
demonstrated GFP expression as early as 2 h p.i. and TR
expression between 9 and 12 h p.i. (data not shown).
Growth curves using high MOI inoculums were performed
with both wild type and MPXV-GFP-tdTR and showed no
significant difference in the amount of cell-or medium-
associated virus (Figure 2c), indicating that incorporation
of the two fluorescent genes had no impact on virus
growth kinetics.
Fluorescence microscopy and a relative fluorescence
assay of IFN-b pre-treated, MPXV-GFP-tdTR infected
cells revealed a significant reduction of GFP expression in
t h ep r e s e n c eo fI F N - b compared to untreated controls
(Figure 3). TR expression was also reduced compared to
untreated controls (Figure 3); however, the amount of
GFP and TR expression in treated cells was similar, sug-
gesting a role for IFN-b in blocking early gene expression.
Pathogenesis in a host system requires that MPXV
spread efficiently from cell to cell. To look at cell-to-cell
spread in vitro, we performed a low MOI growth curve
using MPXV-Zaire. In the presence of IFN-b, the amount
of cell-associated virus was reduced by greater than a log
at 48-72 h p.i. (Figure 4a); however, by 120 h p.i., infec-
tious virus levels were comparable to untreated controls.
A similar trend was observed when medium-associated
virus was titered (Figure 4b). Therefore, MPXV spread is
attenuated in vitro in the presence of IFN-b.
Expression of IFN-induced MxA inhibits MPXV infection
MxA is a large GTPase induced by IFN that has been
shown to have antiviral activity [45-51]. MxA expression
in cells infected with MPXV in the presence of IFN-b was
assessed. Immunostains for MxA and the viral protein
A33 demonstrated a diffuse cytoplasmic pattern of MxA
in uninfected, IFN-b pre-treated cells that was consistent
with previous reports [52] while MxA expression in
MPXV infected cells was only observed when cells were
pre-treated with IFN-b (Figure 5). In infected cells treated
with IFN-b, MxA was localized into distinct punctate
regions, and some co-localization with A33 in the cyto-
plasm and at the site of wrapping was observed (Figure 5).
To determine whether MPXV late protein production
was necessary for the re-distribution of MxA, infected
(and IFN-b treated) cells were incubated with Ara-C
which inhibits viral replication and subsequent late gene
expression. Similar punctate regions of MxA staining were
observed in both the presence and absence of Ara-C in
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cation nor late protein production is necessary for the re-
localization of MxA during MPXV infection.
VA-9, a cell line that constitutively expresses MxA,
[53] and the parental control cell line VN36 [53] were
infected with MPXV-Zaire at a high MOI to look at the
antiviral activity of MxA against MPXV. We observed
an approximately 91% reduction in the amount of infec-
tious virus present in VA-9 cells compared to VN36
control cells (Figure 7a). To confirm these results, we
performed fluorescence microscopy on VA-9 and VN36
cells infected with MPXV-GFP-tdTR at a high MOI,
and the relative fluorescence was measured. Again, we
observed a statistically significant inhibition of infection
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Figure 1 (a) IFN-b titration. HeLa cells were pre-treated for 24 h with the indicated concentrations of IFN-b. After pre-treatment, the cells were either
left uninfected (right) or were infected with MPXV-Zaire at an MOI = 5 in the presence of the indicated concentrations of IFN-b (left). Infected cells were
harvested 24 h p.i., and lysates were titered by plaque assay. Uninfected cells were assayed for viability using a CellTiter-Glo Luminescent Cell Viability
Assay. RLU = relative light units. (b) High MOI growth curve. HeLa cells were either left untreated or were pre-treated for 24 h with 2000 U/ml of IFN-b.
After pre-treatment, the cells were infected with MPXV-Zaire (MOI = 5) in the presence or absence of 2000 U/ml of IFN-b. Cells (left) and medium (right)
were separately harvested at the indicated times, and lysates were titered by plaque assay. Note the different scales in the left and right panels.
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Figure 2 Characterization of MPXV-GFP-tdTR.( a) Vero-E6 cells infected with MPXV-GFP-tdTR were imaged 48 h p.i. by fluorescence
microscopy. A single representative plaque is shown. Green is GFP, red is Tomato Red, and yellow represents the overlap of green and red
fluorescence. (b) Vero-E6 cells infected with MPXV-GFP-tdTR (MOI = 5) in the presence or absence of Ara-C were imaged after 48 h by
fluorescence microscopy. Green is GFP, red is Tomato Red, and yellow represents the overlap of green and red fluorescence. (c) High MOI
growth curve. HeLa cells were infected with MPXV-GFP-tdTR at an MOI = 5. Cells (left) and medium (right) were separately harvested at the
indicated times, and lysates were titered by plaque assay. Note the different scales for cell and media graphs.
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equally reduced in the presence of MxA (Figure 7b),
demonstrating a role for MxA in the inhibition of
MPXV by IFN-b.
It was previously shown that a mutant form of MxA
containing a Glu-to-Arg substitution at amino acid 645
[MxA(E645R)] lost its ability to inhibit infection by vesi-
cular stomatitis virus and African swine fever virus
(ASFV) but retained its inhibitory effect over influenza
virus and thogoto virus [49,53,54]. To test the suscept-
ibility of MPXV to this mutant MxA, VA(R645) cells
were infected with MPXV-Zaire at an MOI = 5. Although
we still observed an approximately 91% inhibition in VA-
9 cells, we observed no reduction of infectious virus pro-
duction in VA(R645) cells (Figure 8), suggesting that
MPXV is resistant to inhibition by MxA(E645R).
Post infection treatment with IFN-b was able to inhibit
MPXV-Zaire
To test the therapeutic limit of IFN-b, HeLa cells infected
at a high MOI with MPXV-Zaire were treated with IFN-b
at 0, 2, 4, 6, 8, or 12 h p.i.. An approximately 91% reduction
in infectious virus was observed when IFN-b was added 6-8
h p.i. (Figure 9a), suggesting that IFN-b can significantly
inhibit MPXV when added during an active infection.
MPXV is highly susceptible to IFN-b inhibition in human
primary cells
Human primary cells more closely resemble an in vivo
situation than immortalized cell lines (such as HeLa cells)
and were, therefore, used to examine the susceptibility of
MPXV under more physiologically relevant conditions.
Normal human dermal fibroblasts that were pre-treated
for 24 h before infection with increasing concentrations of
IFN-b (0-5000 U/ml) were infected with MPXV-Zaire at a
high MOI. The cells were harvested 24 h p.i. and virus
present titered by plaque assay. An approximately 95%
reduction in infectious virus was observed with the lowest
concentration of IFN-b (25 U/ml), with maximum inhibi-
tion of approximately 99% observed at concentrations
greater than or equal to 1000 U/ml (Figure 9b). In HeLa
cells, this level of inhibition was not even seen with the
highest concentration of IFN-b (5000 U/ml) (Figure 1a),
demonstrating that MPXV susceptibility to IFN-b is
enhanced when primary cells are used.
Discussion
In this report, we described the potential use of IFN-b
as a novel anti-MPXV therapeutic. Previous reports
have shown that exogenously introduced type I IFN pro-
tects non-human primates from lesion development
after vaccinia virus challenge [44], and IFN-b expressed
by a recombinant vaccinia virus is 100% effective at pre-
venting mortality in mice [43,44]. Here, we showed that
IFN-b is capable of significantly reducing MPXV infec-
tion. Fluorescence microscopy suggested that IFN-b
treatment resulted in an antiviral state that is capable of
interfering with infection, and high and low MOI
growth curves demonstrated that MPXV production,
release, and spread were reduced by IFN-b.
Figure 3 HeLa fluorescence. HeLa cells were pre-treated for 24 h with the indicated concentrations of IFN-b. After pre-treatment, the cells
were infected with MPXV-GFP-tdTR (MOI = 5) in the presence or absence of 2000 U/ml of IFN-b. The cells were imaged 24 h p.i. by
fluorescence microscopy (left), and relative fluorescence was assayed using a fluorescence microplate reader (right). Green is GFP, red is Tomato
Red, and yellow represents the overlap of green and red fluorescence.
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that the effect of IFN-b on MPXV is multifaceted and
dependent on numerous effector molecules belonging to
the Type I IFN signaling cascade. In this report, we
showed that one such molecule, MxA, has a significant
inhibitory effect on MPXV. MxA has antiviral activity
against numerous RNA viruses including influenza
viruses, bunyaviruses, thogoto virus, measles virus,
human parainfluenza virus 3, vesicular stomatitis virus,
Semliki Forest virus, and hepatitis B virus [45-51], as well
as the DNA-containing ASFV [49]. Like MPXV, ASFV is
a large, double stranded DNA virus that replicates
entirely in the cytoplasm of the infected cell. Similar to
ASFV, we showed that MPXV is inhibited by MxA but is
resistant to inhibition by the mutant MxA(E645R). Addi-
tionally, MxA is relocalized following infection with both
MPXV and ASFV, and this relocalization is independent
of late protein production. In ASFV infected cells, MxA
appears to be recruited to the site of virus assembly.
Similarly, the majority of MxA in MPXV infected cells
appeared to be located at the site of virus envelopment.
MxA relocalization was still observed in the presence of
Ara-C during MPXV infection but not ASFV infection,
suggesting that MxA relocalization is independent of
MPXV replication. We did not investigate the specific
mode of action of MxA against MPXV as this was
beyond the scope of this study which focused predomi-
nantly on the effectiveness of IFN-b against MPXV as
justification for its further development as a therapeutic
against highly pathogenic Orthopoxviruses.H o w e v e r ,t h e
data suggest that the method by which MxA inhibits
MPXV might be similar to its inhibition of ASFV.
T h e r ei se v i d e n c ei nt h el i t e r a t u r et h a tin vitro tests
likely underestimate the inhibitory effect of IFNs on
Orthopoxviruses in vivo, where additional immune
defenses could act in concert with IFN signaling. Type I
IFN has been shown to protect mice and non-human pri-
mates from morbidity and mortality after challenge with
the closely related vaccinia virus [43,44]. Additionally, stu-
dies have shown that as little as a 1-2 log reduction in
MPXV significantly reduces morbidity and mortality in
non-human primates [55]. We, therefore, hypothesize that
the effect of IFN-b on MPXV infectivity would be even
greater in vivo, resulting in significant reductions in mor-
bidity and mortality. In support of this prediction, we
observed a much greater reduction in infectious MPXV by
IFN-b when a primary cell line (normal human dermal
fibroblast cells), which more closely mimics the in vivo
state, was used. Collectively, the data presented in this
report support the further development of IFN-b as a
novel anti-MPXV countermeasure.
Conclusions
Thirty years after the cessation of the smallpox vaccination
campaign, dramatic increases in MPXV prevalence in the
DRC [18] have raised concerns that the increasing size of
the unvaccinated population is allowing for higher rates of
zoonosis, and suggest a much greater risk of transmission
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Page 7 of 15to other susceptible populations worldwide. In 2003, a
chain of seven generations of uninterrupted human-to-
human spread revealed that an unprotected population
could potentially sustain a MPXV outbreak [11]. Addition-
ally, mutations that result in a virus that is better adapted
to humans could strengthen transmissibility and patho-
genesis. Based on information gained during active disease
surveillance studies in the DRC [18], there is growing con-
cern that the introduction of a virulent strain of MPXV
into an area where little or no anti-Orthopoxvirus immu-
nity exists, such as in the United States, could result in an
epidemic with significant public health implications.
Therefore, the development of countermeasures against
MPXV and closely related VARV is of great importance.
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Figure 5 Confocal microscopy of MxA in infected cells. HeLa cells on coverslips were either left untreated or were pre-treated for 24 h with
2000 U/ml of IFN-b. After pre-treatment, the cells were infected with MPXV-Zaire at an MOI = 1 in the presence or absence of 2000 U/ml of
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denote the cell vertices.
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anti-Orthopoxvirus prophylactic. However, these vaccines
are the most reactogenic of all FDA-approved vaccines,
prompting the cessation of their generalized use in 1980
due to the unnecessary risk of complications in the
absence of an active smallpox epidemic [56,57]. Under
current guidelines these vaccines will be contraindicated
for 1 in 5 individuals [5,58,59], including individuals who
have heart disease, skin disorders, and/or have a weakened
immune system [57]. The risks associated with live vac-
cines have prompted the investigation into safer alterna-
tives, including attenuated and subunit vaccines [56,57].
The development of therapeutics that can treat established
infections caused by outbreak or accidental exposure
(such as by laboratory accident) or to minimize/treat
adverse events caused by vaccination is ongoing, and cur-
rently no therapeutics have been licensed for widespread
use against Orthopoxviruses. Additionally, the develop-
ment of at least two therapeutics with distinct mechanisms
of action is required before the destruction of the remain-
ing stores of VARV can even be considered. Cidofovir and
its derivatives [60-63] and Gleevec [64,65] have been
investigated for this purpose. Presently the most promising
candidate is ST-246 which specifically targets the virus by
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Ara-C. Coverslips were harvested, fixed, permeabilized, and immunostained for MxA 24 h p.i.. The coverslips were stained with Hoechst dye,
mounted onto slides, and imaged by confocal microscopy. Green is GFP, red is Tomato Red, blue is Hoechst dye, and white is MxA.
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Page 9 of 15Figure 7 Infection of cells constitutively expressing MxA.( a) VA-9 and VN36 cells were infected with MPXV-Zaire at an MOI = 5. The cells
were harvested and lysed 24 h p.i., and the amount of virus present in the lysates was titered by plaque assay. (b) VA-9 and VN36 cells were
infected with MPXV-GFP-tdTR at an MOI = 5. The cells were imaged 24 h p.i. by fluorescence microscopy (left), and relative fluorescence was
measured using a fluorescence microplate reader (right). Green is GFP, red is Tomato Red, and yellow represents the overlap of green and red
fluorescence.
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Page 10 of 15inhibiting the viral protein F13 [55,66]. In this report, we
investigated the in vitro effectiveness of a novel candidate
therapeutic, IFN-b, against MPXV. IFN-b is an attractive
therapy because it is already in use to treat multiple sclero-
sis, it is readily available and has a well-defined safety pro-
file, and it could be quickly implemented and used off-
label. Due to the limited amount of information available
concerning the function of the various anti-IFN proteins
expressed by Orthopoxviruses (reviewed in the introduc-
tion), particularly the highly pathogenic MPXV and
VARV, data obtained from investigating the therapeutic
potential of IFN-b against these viruses might also prove
to be pivotal in advancing our understanding of immune
evasion by Orthopoxviruses and uncovering the elements
of an effective immune response against these pathogens.
This, in turn, could provide information that would be
influential in guiding the development, testing, and imple-
mentation of other anti-Orthopoxvirus countermeasures.
IFN-b should also be considered for the treatment of
adverse events associated with the smallpox vaccine, parti-
cularly for those conditions where vaccinia immunoglobu-
lin is not recommended or is believed to be of limited
utility. In conclusion, IFN-b should be further developed
for prophylactic and/or therapeutic use against MPXV, as
well as investigated for efficacy against other highly patho-
genic Orthopoxviruses including VARV.
Methods
Cells, viruses, and interferons
VA-9, VN36, and VA(R645) cell lines [53,54] were gener-
ously provided by Dr. Otto Haller (University of Freiburg,
Germany). Monolayers of HeLa cells (ATCC, Manassas,
VA) and normal human dermal fibroblasts (Lonza, Walk-
ersville, MD) were maintained in Dulbecco’s Modifica-
tion of Eagle’s Medium (Cellgro, Manassas, VA)
containing 10% heat-inactivated fetal bovine serum, 1X
glutamine, and 1X penicillin/streptomycin. Monolayers
of Vero-E6, MA-104, VA-9, VN36, and VA(R645) cells
were maintained in Minimum Essential Medium (Cell-
gro, Manassas, VA) containing 10% heat-inactivated fetal
bovine serum, 1X glutamine, and 1X penicillin/strepto-
mycin. Cell counts were obtained before plating to assure
that equal numbers of cells were used for all infections.
All infections were performed in medium containing
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Figure 8 MPXV resistance to MxA(E645R). VA-9, VA(R645), and
VN36 cells were infected with MPXV-Zaire at an MOI = 5. The cells
were harvested and lysed 24 h p.i., and the amount of virus present
in the lysates was titered by plaque assay.
0
%
 
R
e
d
u
c
t
i
o
n
0 Untreated
Hours Post Infection
2468 1 2
20
40
60
80
100
A. A.
%
 
R
e
d
u
c
t
i
o
n
0
20
40
60
80
100
0
[IFN-β] (Units/ml)
200
400
600
800
1000
2000
3000
4000
5000
25
B.
Figure 9 (a) Post-treatment assay. HeLa cells infected with MPXV-
Zaire at an MOI = 5 in the presence or absence of 2000 U/ml of
IFN-b were treated with 2000 U/ml of IFN-b at the indicated times
after infection. The cells were harvested 24 h p.i. and lysates were
titered by plaque assay. (b) Infection of fibroblast with MPXV.
Normal human dermal fibroblasts were pre-treated for 24 h with
2000 U/ml of IFN-b. After pre-treatment, the cells were infected with
MPXV-Zaire (MOI = 5) in the presence or absence of 2000 U/ml of
IFN-b. The cells were harvested 24 h p.i., and the amount of virus
present in the lysates was titered by plaque assay.
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Page 11 of 152.5% heat-inactivated fetal bovine serum, 1X glutamine,
and 1X penicillin/streptomycin. MPXV-Zaire-1971-005
was previously described [67,68]. Human IFN-b 1a was
obtained from PBL InterferonSource (Piscataway, NJ). As
described on the data sheet from the manufacturer, this
product was generated from cDNA isolated from human
fibroblast mRNA expressed in CHO cells; it is not PEGy-
lated. Upon arrival, the IFN was distributed to aliquots to
minimize freeze-thawing, and stored at -80°C as recom-
mended by PBL Interferon Source to maintain activity.
MPXV-GFP-tdTR generation and characterization
MPXV-GFP-tdTR, which expresses GFP from the early
viral synthetic E/L promoter and tandem dimer Tomato
Red (TR) from the late viral promoter 11, was generated
as follows. An expression plasmid containing both fluores-
cent inserts was obtained from Dr. Grant McFadden (Uni-
versity of Florida). Confluent monolayers of Vero-E6 cells
infected with MPXV-Zaire (MOI = 1) were transfected
with 2 μg of plasmid DNA in the presence of Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Cells were harvested 24 h p.i.
and lysed by freeze-thawing, and the lysate was used to
infect Vero-E6 cells. Plaques that fluoresced both green
and red were purified a total of 4 times on Vero-E6 cells,
and then amplified to high titer in MA-104 cells. The
resulting purified recombinant virus, MPXV-GFP-tdTR,
contained both fluorescent tags inserted into the inter-
genic region between J4R and J5L. Sequencing of this
region confirmed proper insertion of tdTR and GFP. A
plaque assay and high MOI (MOI = 5) growth curve were
performed as described previously [69] on confluent
monolayers of Vero-E6 cells.
To confirm proper expression of GFP and tdTR, Vero-
E6 cells were infected with MPXV-GFP-tdTR (MOI = 5)
in the presence or absence of 50 μg/ml of Ara-C. After a
1 h incubation, the inoculum was removed, the cells
washed, and fresh medium with and without 50 μg/ml of
Ara-C was added. Images were acquired 48 h p.i. using a
Nikon Eclipse te2000-s fluorescence microscope equipped
with a SPOT RT Monochrome camera and overlaid using
Adobe PhotoShop software.
IFN-b titration assay
Monolayers of HeLa cells (1 × 10
6 cells/well) or normal
human dermal fibroblasts (3 × 10
5 cells/well) were either
left untreated or were pretreated with 0, 200, 400, 600,
800, 1000, 2000, 3000, 4000, or 5000 U/ml of human IFN-
b 1a (PBL InterferonSource, Piscataway, NJ). The cells
were infected 24 h later with MPXV-Zaire at an MOI of 5
in the presence or absence of IFN-b. After 1 h, the inocu-
lum was removed, the cells washed, and fresh media with
or without IFN-b was added. The cells were harvested
24 h p.i., lysed by 3 cycles of freeze-thawing/sonication,
and virus titers determined by plaque assay as described
above.
To assess the therapeutic limit of IFN-b, cells were
treated with 2000 U/ml of IFN-b either 0, 2, 4, 6, 8, or
12 h p.i. and infections and viral titers were performed
as described above.
Growth curves
High MOI (MOI = 5) and low MOI (MOI = 0.01) growth
curves were performed in duplicate as described pre-
viously [69]. Briefly, HeLa cells were either left untreated
or were pre-treated with 2000 U/ml of IFN-b. The cells
were infected 24 h later with MPXV-Zaire in the presence
or absence of 2000 U/ml of IFN-b. For the 0 h time point,
the inoculum was immediately removed, the cells were
washed, 1 ml of fresh medium was added to the cells, and
the cells and medium were immediately harvested. For all
other time points, the inoculum was removed 1 h p.i., the
cells were washed, and 1 ml of fresh medium with or with-
out 2000 U/ml of IFN-b was added. Fresh IFN-b was
added to the medium every 24 h p.i.. Cells and medium
were harvested separately at 0, 4, 12, 24, and 48 h p.i. for
the high MOI growth curve, and at 0, 24, 48, 72, 96, and
120 h p.i. for the low MOI growth curve. Cells were lysed
by three cycles of freeze-thawing/sonication (medium har-
vests were not freeze-thawed to maintain the integrity of
viral membranes), and viral titers were determined by pla-
que assay as described above.
Fluorescence and confocal microscopy
HeLa cells grown on coverslips were either left untreated
or were pre-treated 24 h before infection with 2000 U/ml
of IFN-b. Cells were infected 24 h later with MPXV-GFP-
t d T Ro rM P X V - Z a i r ea taM O Io f5i nt h ep r e s e n c eo r
absence of IFN-b and/or Ara-C (50 μg/ml). Cells were
either imaged 24 h p.i. by using aNikon Eclipse te2000-s
fluorescence microscope equipped with a SPOT™ RT
Monochrome camera (and overlaid using Adobe Photo-
Shop software) or were fixed in phosphate-buffered saline
(PBS) containing 4% paraformaldehyde in preparation for
immunostaining. Fixed cells were permeabilized with PBS
containing 0.1% Triton X-100 (Sigma-Aldrich, St. Louis,
MO), quenched with PBS containing 0.1X glycine (Sigma-
Aldrich, St. Louis, MO), and stained with an anti-MxA
m A b( S i g m aA l d r i c h ,S t .L o u i s ,M O )f o l l o w e db ye i t h e r
Alexa Fluor 568-conjugated goat anti-rabbit IgG (Invitro-
gen, Carlsbad, CA) or Alexa Fluor 647-conjugated goat
anti-rabbit IgG (Invitrogen, Carlsbad, CA). Additionally,
cells infected with MPXV-Zaire were stained with an anti-
A33 monoclonal antibody (mAb) (generously provided by
Dr. Jay Hooper, USAMRIID) followed by Alexa Fluor 488-
conjugated goat anti-mouse IgG (Invitrogen, Carlsbad,
CA). The coverslips were thoroughly washed and, follow-
ing staining with Hoechst dye for 30 min, were mounted
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Page 12 of 15onto slides using Fluoromount-G (SouthernBiotech, Bir-
mingham, AL). Images were captured using a Leica TCS
SP5 confocal microscope and overlaid using Leica Appli-
cation Suite software. All relative fluorescence measure-
ments were acquired using a SpectraMax Gemini EM
Fluorescence Microplate Reader (Molecular Devices, Sun-
nyvale, CA).
Infection of VA-9, VN36, and VA(R645) cell lines
VA-9, VN36, and VA(R645) cells were infected with
MPXV-Zaire or MPXV-GFP-tdTR at an MOI of 5. After
absorption for 1 h, the inoculum was removed, the cells
were washed, and fresh medium was added. The cells
infected with MPXV-Zaire were harvested 24 h p.i. and
lysed by three cycles of freeze-thawing/sonication, and
viral titers were determined by plaque assay as described
above. Fluorescence microscopy was performed 24 h p.i.
on cells infected with MPXV-GFP-tdTR using a Nikon
Eclipse te2000-s fluorescence microscope equipped with a
SPOT RT Monochrome camera and overlaid using Adobe
PhotoShop software. Relative fluorescence measurements
were acquired using a SpectraMax Gemini EM Fluores-
cence Microplate Reader (Molecular Devices, Sunnyvale,
CA).
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